These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Winkel LP; Van den Hout JM; Kamphoven JH; Disseldorp JA; Remmerswaal M; Arts WF; Loonen MC; Vulto AG; Van Doorn PA; De Jong G; Hop W; Smit GP; Shapira SK; Boer MA; van Diggelen OP; Reuser AJ; Van der Ploeg AT Ann Neurol; 2004 Apr; 55(4):495-502. PubMed ID: 15048888 [TBL] [Abstract][Full Text] [Related]
11. Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy. Winkel LP; Kamphoven JH; van den Hout HJ; Severijnen LA; van Doorn PA; Reuser AJ; van der Ploeg AT Muscle Nerve; 2003 Jun; 27(6):743-51. PubMed ID: 12766987 [TBL] [Abstract][Full Text] [Related]
12. Infantile Pompe disease: clinical and genetic characteristics with an experience of enzyme replacement therapy. Cho A; Kim SJ; Lim BC; Hwang H; Park JD; Kim GB; Jin DK; Lee J; Ki CS; Kim KJ; Hwang YS; Chae JH J Child Neurol; 2012 Mar; 27(3):319-24. PubMed ID: 21940687 [TBL] [Abstract][Full Text] [Related]
13. Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy. Papadimas GK; Spengos K; Konstantinopoulou A; Vassilopoulou S; Vontzalidis A; Papadopoulos C; Michelakakis H; Manta P Clin Neurol Neurosurg; 2011 May; 113(4):303-7. PubMed ID: 21216089 [TBL] [Abstract][Full Text] [Related]
14. Long-term enzyme-replacement therapy (ERT) with alglucosidase alfa: Evolution of two siblings with juvenile late-onset Pompe disease. Rafael Bretón Martínez J; Martínez AC J Neurol Sci; 2015 Nov; 358(1-2):459-60. PubMed ID: 26279333 [No Abstract] [Full Text] [Related]
15. Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Klinge L; Straub V; Neudorf U; Schaper J; Bosbach T; Görlinger K; Wallot M; Richards S; Voit T Neuromuscul Disord; 2005 Jan; 15(1):24-31. PubMed ID: 15639117 [TBL] [Abstract][Full Text] [Related]
16. 24-months results in two adults with Pompe disease on enzyme replacement therapy. Vielhaber S; Brejova A; Debska-Vielhaber G; Kaufmann J; Feistner H; Schoenfeld MA; Awiszus F Clin Neurol Neurosurg; 2011 Jun; 113(5):350-7. PubMed ID: 21477922 [TBL] [Abstract][Full Text] [Related]
17. Sixty six-month follow-up of muscle power and respiratory function in a case with adult-type Pompe disease treated with enzyme replacement therapy. Isayama R; Shiga K; Seo K; Azuma Y; Araki Y; Hamano A; Takezawa H; Kuriyama N; Takezawa N; Mizuno T; Nakagawa M J Clin Neuromuscul Dis; 2014 Jun; 15(4):152-6. PubMed ID: 24872213 [TBL] [Abstract][Full Text] [Related]
18. Making diagnosis of Pompe disease at a presymptomatic stage: to treat or not to treat? Laloui K; Wary C; Carlier RY; Hogrel JY; Caillaud C; Laforêt P Neurology; 2011 Aug; 77(6):594-5. PubMed ID: 21753173 [No Abstract] [Full Text] [Related]
19. Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail. Kikuchi T; Yang HW; Pennybacker M; Ichihara N; Mizutani M; Van Hove JL; Chen YT J Clin Invest; 1998 Feb; 101(4):827-33. PubMed ID: 9466978 [TBL] [Abstract][Full Text] [Related]
20. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]